249 related articles for article (PubMed ID: 32404973)
21. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?
Frustaci AM; Montillo M; Picardi P; Mazzucchelli M; Cairoli R; Tedeschi A
Expert Rev Hematol; 2016 Jul; 9(7):679-93. PubMed ID: 27253240
[TBL] [Abstract][Full Text] [Related]
22. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
[TBL] [Abstract][Full Text] [Related]
23. Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia.
Kostopoulou F; Gabillaud C; Chapiro E; Grange B; Tran J; Bouzy S; Degaud M; Ghamlouch H; Le Garff-Tavernier M; Maloum K; Choquet S; Leblond V; Gabarre J; Lavaud A; Morel V; Roos-Weil D; Uzunov M; Guieze R; Bernard OA; Susin SA; Tournilhac O; Nguyen-Khac F;
Cancer Med; 2019 Jun; 8(6):3131-3141. PubMed ID: 31066214
[TBL] [Abstract][Full Text] [Related]
24. Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.
Arnason JE; Brown JR
Curr Oncol Rep; 2017 Sep; 19(9):61. PubMed ID: 28755313
[TBL] [Abstract][Full Text] [Related]
25. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
26. BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
Daniel C; Mato AR
Clin Adv Hematol Oncol; 2017 Mar; 15(3):210-218. PubMed ID: 28398276
[TBL] [Abstract][Full Text] [Related]
27. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
28. An update on: molecular genetics of high-risk chronic lymphocytic leukemia.
Moia R; Patriarca A; Deambrogi C; Rasi S; Favini C; Kodipad AA; Schipani M; Gaidano G
Expert Rev Hematol; 2020 Feb; 13(2):109-116. PubMed ID: 31774349
[No Abstract] [Full Text] [Related]
29. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Koehrer S; Burger JA
Clin Adv Hematol Oncol; 2016 Jan; 14(1):55-65. PubMed ID: 27057669
[TBL] [Abstract][Full Text] [Related]
30. Critical molecular pathways in CLL therapy.
Ferrer G; Montserrat E
Mol Med; 2018 Mar; 24(1):9. PubMed ID: 30134797
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
32. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
33. The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
Aw A; Brown JR
Leuk Lymphoma; 2017 Oct; 58(10):2287-2297. PubMed ID: 28482721
[TBL] [Abstract][Full Text] [Related]
34. Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
Mato A; Jauhari S; Schuster SJ
Am J Hematol; 2015 Jul; 90(7):657-64. PubMed ID: 25808792
[TBL] [Abstract][Full Text] [Related]
35. [Inhibition of B cell receptor signaling: a first targeted therapeutic approach for chronic lymphocytic leukemia and other B cell lymphomas].
Mráz M; Doubek M; Mayer J
Klin Onkol; 2013; 26(3):179-85. PubMed ID: 23763320
[TBL] [Abstract][Full Text] [Related]
36. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Kurtz SE; Eide CA; Kaempf A; Khanna V; Savage SL; Rofelty A; English I; Ho H; Pandya R; Bolosky WJ; Poon H; Deininger MW; Collins R; Swords RT; Watts J; Pollyea DA; Medeiros BC; Traer E; Tognon CE; Mori M; Druker BJ; Tyner JW
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):E7554-E7563. PubMed ID: 28784769
[TBL] [Abstract][Full Text] [Related]
37. Targeting B cell receptor signalling in cancer: preclinical and clinical advances.
Burger JA; Wiestner A
Nat Rev Cancer; 2018 Mar; 18(3):148-167. PubMed ID: 29348577
[TBL] [Abstract][Full Text] [Related]
38. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
[TBL] [Abstract][Full Text] [Related]
39. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
[TBL] [Abstract][Full Text] [Related]
40. Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
Valla K; Flowers CR; Koff JL
Expert Opin Investig Drugs; 2018 Jun; 27(6):513-522. PubMed ID: 29855199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
